Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma
Crossref DOI link: https://doi.org/10.1007/s00280-014-2479-8
Published Online: 2014-05-10
Published Print: 2014-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Mahalingam, Devalingam
Malik, Laeeq
Beeram, Muralidhar
Rodon, Jordi
Sankhala, Kamalesh
Mita, Alain
Benjamin, Daniel
Ketchum, Norma
Michalek, Joel
Tolcher, Anthony
Wright, John
Sarantopoulos, John
Text and Data Mining valid from 2014-05-10